Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - ciclopirox olamine 1%{relative} - topical solution - 1% w/v - active: ciclopirox olamine 1%{relative}

Izrael - angličtina - Ministry of Health

sanofi - aventis israel ltd - levofloxacin as hemihydrate - solution for infusion - levofloxacin as hemihydrate 5 mg/ml - levofloxacin - levofloxacin - in adults for whom intravenous therapy is considered to be appropriate, tavanic solution for infusion is indicated for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: community- acquired pneumonia, complicated urinary tract infections including pyelonephritis, skin and soft tissue infections.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate,doxylamine succinate,paracetamol -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - docetaxel -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - docetaxel -

Evropská unie - angličtina - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - drugs used in diabetes - diabetes mellitus where treatment with insulin is required. insulin human winthrop rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus.

Evropská unie - angličtina - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).

Evropská unie - angličtina - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - lixisenatide -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - lixisenatide -